Related Experiment Videos
Dermatological toxicity from chemotherapy containing 5-fluorouracil
1Oncology Service, Institute for Digestive Diseases S. De Bellis, Castellana Grotte (Ba), Italy.
Journal of Chemotherapy (Florence, Italy)
|December 1, 1994
Summary
This study observed dermatological toxicities in 81 patients receiving 5-Fluorouracil (5-FU) chemotherapy. While uncommon, skin reactions like hyperpigmentation and palmar-plantar erythrodysesthesia (PPES) occurred, highlighting the need for monitoring 5-FU side effects.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- 5-Fluorouracil (5-FU) is a key antimetabolite in cancer therapy.
- Common adverse effects include gastrointestinal and bone marrow issues.
- Neurological, ocular, and dermatological toxicities are less frequent but significant.
Purpose of the Study:
- To report cases of dermatological toxicity associated with 5-FU chemotherapy.
- To investigate the incidence of skin reactions in patients treated with bolus 5-FU.
- To contribute to understanding the pathogenesis of 5-FU-induced cutaneous adverse events.
Main Methods:
- Retrospective analysis of 81 patients treated with 5-FU combination chemotherapy via bolus injection.
- Data collected from January 1991 to December 1993.
- Documentation of all observed dermatological adverse events.
Main Results:
- Ten cases of dermatological toxicity were identified among 81 patients.
- One patient experienced palmar-plantar erythrodysesthesia (PPES).
- Other reported manifestations included hyperpigmentation and maculo-papular eruption.
Conclusions:
- Dermatological toxicities, though unusual, can occur with 5-FU chemotherapy.
- Palmar-plantar erythrodysesthesia (PPES) is a notable, albeit infrequent, adverse reaction.
- Further research into the etiopathogenesis of 5-FU-induced skin reactions is warranted.